Teva Homepage Print this page Site Map
About TevaInvestor RelationsTeva Worldwide

Press Releases

Jerusalem, Israel, July 1, 2009
Teva Announces Approval and Launch of Tri-Lo Sprintec Tablets

Jerusalem, Israel and Ewing, New Jersey, June 30, 2009
Teva and Antares Announce FDA Approval of Needle-Free Injector Product for Administration of Tev-Tropin® (Human Growth Hormone)

Jerusalem, Israel, June 18, 2009
Court Grants Teva Summary Judgment Of Non-Infringement On Eloxatin®

Jerusalem, Israel, June 9, 2009
Teva to Present at the Goldman Sachs 30th Annual Global Healthcare Conference

Jerusalem, Israel, May 25, 2009
Teva to Present at the Sanford C. Bernstein & Co., LLC Twenty-Fifth Annual Strategic Decision Conference 2009

Jerusalem, Israel, May 14, 2009
Federal Circuit Affirms Denial of Preliminary Injunction Regarding Teva's Generic Protonix® Tablets

Jerusalem, Israel and Basel, Switzerland, May 14, 2009
Lonza and Teva Announce Receipt of Regulatory Approval

Jerusalem, Israel, May 14, 2009
Teva Announces Approval And Launch Of Generic Urso 250® And Urso Forte®

Jerusalem, Israel, May 13, 2009
Teva Provides Update On Generic Actonel® Litigation

Jerusalem, Israel, May 13, 2009
Teva Announces Presentations At Bank Conferences

Jerusalem, Israel, May 6, 2009
Teva Announces Extension of Patent Protection for Azilect®

Jerusalem, Israel, May 5, 2009
Teva reports First Quarter 2009 Results

Jerusalem, Israel, Lund, Sweden and Seattle, Washington, April 28, 2009
New Data Illustrate Novel Mechanism of Action of Laquinimod, An Oral Compound For The Treatment of Multiple Sclerosis

Jerusalem, Israel, April 28, 2009
Long-Term Study with COPAXONE® Indicated Protective Effect on Brain Tissue in Multiple Sclerosis Patients

Jerusalem, Israel, April 23, 2009
Teva Comments on Generic Evista® Preliminary Injunction

Jerusalem, Israel, April 22, 2009
Teva to Present New Data on its Innovative Therapies for Multiple Sclerosis and Parkinson's Disease at the Upcoming 2009 American Academy of Neurology Annual Meeting

Jerusalem, Israel, April 20, 2009
Teva to Report First Quarter 2009 Financial Results on May 5, 2009

Jerusalem, Israel, April 2, 2009
Teva Introduces First Generic Adderall XR® Capsules in the United States

Jerusalem, Israel, April 1, 2009
Teva Announces Approval of Generic Yaz® Tablets

Jerusalem, Israel, March 27, 2009
Teva Announces Approval and Launch of Generic Topamax® Tablets

Jerusalem, Israel, March 25, 2009
Teva Announces FDA Response to Citizen Petition

Jerusalem, Israel and Scottsdale, Arizona, March 19, 2009
Teva and Medicis Announce Settlement Agreement

Jerusalem, Israel, March 18, 2009
Teva Announces Approval and Launch of Generic Solodyn® Extended-Release Tablets

Jerusalem, Israel, March 17, 2009
Study Demonstrates that Qvar® is More Likely to Achieve Successful Asthma Control with Less Exacerbations

Jerusalem, Israel, March 16, 2009
Teva to Present at the Cowen and Company 29th Annual Healthcare Conference

Jerusalem, Israel, March 11, 2009
Teva to Present at the Barclays Capital Global Healthcare Conference

Jerusalem, Israel, March 3, 2009
Copaxone® Approved by the FDA for Patients with a First Clinical Event Suggestive of Multiple Sclerosis

Jerusalem, Israel, February 17, 2009
Teva Provides 2009 Financial Outlook

Jerusalem, Israel, February 17, 2009
Teva Reports Record Full Year 2008 and Fourth Quarter Results

Jerusalem, Israel and Lund, Sweden, February 12, 2009
Oral Laquinimod for Multiple Sclerosis Granted Fast Track Status by FDA

Jerusalem, Israel, February 11, 2009
Teva Announces Approval and Launch of Generic Imitrex® Tablets

Jerusalem, Israel, February 4, 2009
Copaxone® is Approved for Treatment of Patients with a First Clinical Event Suggestive of Multiple Sclerosis

Jerusalem, Israel, January 30, 2009
Teva Announces Approval of Generic Risperdal ® Oral Solution

Jerusalem, Israel, January 27, 2009
Teva to Report Fourth Quarter and Full Year 2008 Financial Results on February 17, 2009

Jerusalem, Israel, and Basel, Switzerland, January 20, 2009
Teva and Lonza Announce Strategic Partnership to Become a Leading Global Provider of Biosimilars

Jerusalem, Israel, January 8, 2009
Teva to Present at the 27th Annual J.P. Morgan Healthcare Conference

Jerusalem, Israel, January 7, 2009
Teva to Present at the Goldman Sachs Healthcare CEOs Unscripted Conference

Jerusalem, Israel, January 5, 2009
Teva Announces Amir Elstein Joins Board of Directors



Archive:  2008  2007  2006  2005  2004  2003  2002  2001  2000  1999